Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lee's Pharm to Start China Trials of In-licensed PD-L1 Candidate

publication date: Jan 29, 2018

A subsidiary of Lee's Pharm received permission to begin China clinical trials of ZKAB001, a PD-L1 immuno-oncology monoclonal antibody. Lee's Pharm, a Hong Kong company, in-licensed greater China rights to the candidate from San Diego's Sorrento Therapeutics in 2014 in a deal that could be worth up to $50 million. Lee's Pharm was granted approval to test ZKAB001 in three cancer indications. Its subsidiary, China Oncology Focus, is in charge of developing the drug. More details....

Stock Symbols: (HK: 0950) (NSDQ: SRNE)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China